Abstract:HomeHypertensionVol. 71, No. 6Could 130/80 mm Hg Be Adopted as the Diagnostic Threshold and Management Goal of Hypertension in Consideration of the Characteristics of Asian Populations? Free AccessArticle CommentaryPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessArticle CommentaryPDF/EPUBCould 130/80 mm Hg Be Adopted as the Diagnostic Threshold and Management Goal of Hypertension in Consideration of the Characteristics of Asian Populations? Kazuomi Kario and Ji-Guang Wang Kazuomi KarioKazuomi Kario From the Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan (K.K.) and Hypertension Cardiovascular Outcome Prevention and Evidence in Asia (HOPE Asia) Network, Tochigi, Japan (K.K., J.-G.W.). and Ji-Guang WangJi-Guang Wang Shanghai Key Laboratory of Hypertension, Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.) and Hypertension Cardiovascular Outcome Prevention and Evidence in Asia (HOPE Asia) Network, Tochigi, Japan (K.K., J.-G.W.). Originally published23 Apr 2018https://doi.org/10.1161/HYPERTENSIONAHA.118.11203Hypertension. 2018;71:979–984Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: January 1, 2018: Previous Version 1 See related article, pp e13–e115This commentary discusses the practical feasibility of the 2017 American Heart Association/American College of Cardiology (AHA/ACC) guidelines1 for the management of hypertension and the ideal direction of blood pressure (BP) prevention, detection, evaluation, and management for achieving a goal of zero cardiovascular events in Asia.Hypertension is a massive global burden on healthcare that indiscriminately affects both high- and low-income countries. However, there are significant ethnic differences in the determinants of hypertension and cardiovascular disease.2,3 The 2017 AHA/ACC guidelines for the prevention, detection, evaluation, and management of high BP in adults changed the diagnostic threshold and the management goal of BP from 140/90 to 130/80 mm Hg. This change in the BP threshold raises 2 important practical considerations for the treatment of hypertension in Asian countries. Because of the stronger BP-dependent characteristics of cardiovascular disease in Asians compared with Westerners, the reduction to a BP goal of 130/80 mm Hg is right in the front of the figure universal management of hypertension. However, because of various cultural and socioeconomic factors specific to Asian countries, the BP control in these countries was not sufficient even when the 140/90 mm Hg threshold was used. The shift of the BP threshold to 130/80 mm Hg level will significantly increase the number of patients with hypertension or uncontrolled hypertension to ≈50% of all Asian adults living in Asian countries.Benefit of Earlier Treatment Initiation Based on the 130/80 mm Hg BP ThresholdThe goal of the management of hypertension is not reducing BP per se but rather preventing cardiovascular events. From this view point, earlier diagnosis and treatment of hypertension is effective for reducing cardiovascular events later in life. The diagnosis of hypertension is based on the average of BP measurements taken, but cardiovascular events may be triggered by BP surge (a pressor component of BP variability).There are various phenotypes of BP variability with different time phases. In order from shortest to longest, these include beat-by-beat, acute trigger-specific (with triggers, such as physical and mental stress, strain, cold temperature, and poor sleep), positional, diurnal, day-by-day, seasonal, and yearly BP variability. When the peaks of these pressor components of BP variability (BP surges) are synchronized, a dynamic surge BP is generated (ie, the resonance hypothesis of BP surge; Figure 1).4,5 In younger individuals, each BP surge is small, and the synchronized BP surge is physiological. With aging, however, the amplitude of each BP surge increases, and the synchronized dynamic BP surge becomes pathological, with greater potential to trigger cardiovascular events. Especially in high-risk patients with cardiovascular risk factors, the exaggerated dynamic BP surge can reach peripheral sites without absorption at the stiffened aorta, resulting in the triggering of cardiovascular events.Download figureDownload PowerPointFigure 1. The impact of age-related risk reduction of surge blood pressure (BP) by the shift of the average BP from 140/90 to 130/80 mm Hg as the diagnostic threshold and treatment goal of hypertension. The earlier intervention has a greater protective effect on the age-related cardiovascular burden of exaggerated (dynamic) surge BP. The dynamic surge BP is generated by the synchronization of surge BPs with different time phases (this is known as the Resonance hypothesis). App indicates application software; CKD, chronic kidney disease; CV, cardiovascular; HIT, health information technology (such as applications for remote monitoring and self-monitoring of BP); and PM2.5, particulate matter 2.5.The age-related increase in the dynamic BP surge would be much steeper than that in the average BPs. Thus, considering that the average BP-based diagnosis and goal seems to underestimate the risk of dynamic BP surge, the earlier treatment of hypertension based on an average BP diagnostic threshold and management goal of 130/80 mm Hg will do much more to reduce the cumulative risk burden of exaggerated surge BP than the previous threshold of 140/90 mm Hg (Figure 1). Moreover, the benefit may be greater in the Asian population than in Westerners when we consider the following characteristics of Asian populations.Asian Characteristics of HypertensionWe recently presented a consensus report on improving the hypertension management in Asian patients by taking into account the various characteristics unique to this population.6 For example, the phenotypes of cardiovascular disease, stroke, and heart failure, which are closely associated with BP, are more common in Asia. Moreover, the association between hypertension and cardiovascular disease is stronger in Asian countries than Western countries. In addition, stroke is more common than coronary artery disease in Asian people, whereas the reverse is true in Western populations. In the recent prospective HONEST study (Home Blood Pressure Measurement With Olmesartan Naive Patient, to Establish Standard Target BP), the incidence of stroke was 2.8× higher than that of myocardial infarction (2.92 versus 1.03/1000 person-years) in on-treatment hypertensive patients.7 The slope of the association between higher BP levels and cardiovascular events has also been shown to be steeper in Asians compared with Western populations.8 In consideration of these Asian-specific characteristics, antihypertensive medication targeting a lower systolic BP (SBP; eg, <130 mm Hg) would be of greater benefit in Asians than in Westerners, especially for reducing the risk of stroke and heart failure.A country-based, regional approach factoring in ethnic differences in the pathogenesis and clinical characteristics of hypertension is important for effective practical management. In our previous survey of the consciousness of the management of hypertension in Asia, 87% of all Asian physicians answered that they did take into consideration the Asian lifestyle and Asian-specific characteristics of hypertension, and 92% recognized the need for Asian-specific guidelines for the management of hypertension.9 Furthermore, the acquisition of global comparative evidence for the efficacy of different drugs could contribute to the development of region-specific guidelines for hypertension management. Although this approach is also relevant and applicable to Europe, it can be argued that the call to action is greater and more urgent in Asia. This is because, given the wider disparities in practice and in healthcare delivery and infrastructure in these rapidly developing countries, any efforts aimed at formally standardizing and optimizing key management practices could have a more immediate impact on treatment gaps. Moreover, there is less available evidence in Asian populations, and thus further clinical studies to clarify Asian-specific characteristics would ultimately improve the management of hypertension.HOPE Asia NetworkWe recently established the HOPE Asia Network (Hypertension, Brain, Cardiovascular and Renal Outcome Prevention and Evidence in Asia).10 The HOPE Asia Network is made up of several groups of Asian hypertension researchers—for example, the Asia [email protected] Investigators' Meeting and the COME Asia-MHDG (Characteristics on the Management of Hypertension in the Asia-Morning Hypertension Discussion Group)—which have been studying and discussing the characteristics of hypertension and cardiovascular–renal disease in Asian populations. Its ultimate mission is to improve the management of hypertension and organ protection toward the achievement of zero cardiovascular events in Asia. The activity of the HOPE Asia Network is based on 3 initiatives: (1) examining and analyzing all of the existing evidence-related to hypertension, (2) forming a consensus on hot clinical topics of hypertension, and (3) conducting Asia-wide clinical studies of hypertension. In addition, the HOPE Asia Network is proud to be a member organization of The World Hypertension League and looks forward to contributing actively to World Hypertension League's mission of confronting the global epidemic of hypertension and the huge burden of premature death and disability that results from this condition.As a first step in pursuing the objectives of the HOPE Asia Network, we have collected studies in the literature concerning the status of BP control in Asian countries (Figure 2).11,12 This body of evidence suggests that the awareness, treatment, and control rates of hypertension are generally low in Asia but also markedly different among the individual Asian countries. Even within single Asian countries, the broad regional, economic, and cultural differences seem to affect BP and BP control. The hypertension data in Figure 2 were defined by the 140/90 mm Hg threshold. As the new threshold from the 2017 AHA/ACC guidelines, 130/80 mm Hg is increasingly adopted, the BP control rate of hypertension is expected to decrease dramatically. Already in the United States, application of the new criteria has resulted in an increase in the prevalence of hypertension and uncontrolled BP, especially in younger adults.13 This increase should be even more pronounced in Asian countries than in Western countries. One of the effects of this change may be an increase in the cost of antihypertensive medication worldwide. However, the increased prevalence of hypertension does not necessarily mean that a strict medication regimen should be recommended. Instead, lifestyle modifications started earlier in life (diet, exercise, good sleep, good environment, etc) facilitated by health information technology (eg, applications for smart phone or computer), especially reducing salt intake and body weight, are recommended as a first-line treatment in Asia (Figure 2).Download figureDownload PowerPointFigure 2. Awareness, treatment, and control rate of hypertension in Asian countries and regions. NA indicates data not available.Obesity and Salt Intake in AsiaThe impact of obesity on high BP may differ between Asians and whites. Asians are likely to develop high BP even with mild obesity. From the viewpoint of the risk of the 2017 AHA/ACC Elevated BP/Stage I hypertension (previous prehypertension), the impact of body mass index 25 kg/m2 in Japanese is almost equivalent to that of body mass index 30 kg/m2 in the US population.14 Obesity and metabolic syndrome are known to increase salt sensitivity. Asians are likely to have a genetic predisposition to salt sensitivity.15 Compounding this problem, Asians tend to have a higher salt intake.16 Thus, the increase in salt sensitivity caused even by mild obesity could readily cause high BP in Asians who are already prone to high salt sensitivity and high salt intake.Salt intake is gradually decreasing in Japan but remains high at >10 g/d. In our survey in hypertensive patients recruited from general practitioner-based clinics in Tochigi prefecture, the average salt intake (estimated by concentrations of sodium and creatinine in spot urine) was 10.2 g/d, and the prevalence of well-controlled patients with a salt intake of <6 g/d was only 6.7%.17 We confirmed that a moderate salt restriction of −1.8 g/d (targeted 6.0 g/d, baseline 8.6 g/d, achieved 6.8 g/d), directed by a nutritionist, will significantly reduce clinic, home, and ambulatory BP (−7.3 mm Hg for 24-hour SBP) in medicated hypertensive patients.18Thus, salt restriction to salt intake <6.0 g/d and body weight moderation to body mass index <25 kg/m2 are effective approaches, especially in Asians.Twenty-Four–Hour Ambulatory BP Profile in AsiaThe 2017 ACC/AHA guidelines recommend that hypertension be managed using home BP monitoring and ambulatory BP monitoring.1 A 24-hour BP profile is determined partly by an individual's genetic factors, but it is also strongly affected by a variety of cultural factors (eg, food, lifestyle, and traditions) and environmental factors (eg, temperature, atmospheric pressure, humidity, and seasonal changes).4,5BP variability may be greater in the Asian than the Western population.6 Exaggerated morning surge in BP may be more prevalent in Asian people, and, even when clinic BPs are normal, Asians are more likely to have morning and nocturnal hypertension. It is, therefore, important to assess out-of-clinic BP in Asian patients, especially first in the morning, and ideally during the sleep period as well. A recent analysis of data from the international ambulatory BP monitoring registry, the ARTEMIS study (International Ambulatory Blood Pressure Registry: Telemonitoring of Hypertension and Cardiovascular Risk Project), demonstrated that the prevalence of masked hypertension is higher in Asians than in Westerners.19 In the same database, even though the clinic BP is comparable between Japanese and Western hypertensive patients, the Japanese hypertensive patients have an exaggerated morning surge in BP compared with their Western counterparts.20 In the patients with drug-resistant hypertension, who were recruited according to the same global entry criteria of the Simplicity HTN-3 and HTN-Japan trials for catheter-based renal denervation, even when the clinic BP was comparable, Japanese patients had higher morning BP level and greater morning BP surge than the white and black patients.21In addition, Asians are likely to have isolated nocturnal hypertension.22 In population cohorts, the nocturnal BP fall may be less in Asians than in the Westerners.23 In addition, isolated nocturnal hypertension is significantly associated with arterial stiffness in the Chinese population.24 Nocturnal hypertension is associated with high sodium intake and salt sensitivity,25which seems to be specific characteristics of hypertension in Asian populations. The international epidemiological data have demonstrated that increased nocturnal BP is a powerful predictor of cardiovascular outcomes, especially in treated hypertensive patients.26 Thus, the impact of controlling hypertension for a 24-hour period would be greater in Asians.6Facilitation of a Home BP-Guided Approach in AsiaAs a second step in the activities of the HOPE Asia Network, we have focused on home BP values. Specifically, we have focused on a morning home BP-guided approach as the most effective strategy to achieve zero cardiovascular events in Asia.27–30The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014) first documented a home BP-guided approach as the most effective practical approach in clinical practice.31 The 2017 ACC/AHA guidelines recommended home BP monitoring for confirmation of the diagnosis of hypertension and for titration of BP-lowering medication, in conjunction with telehealth counseling (recommendation: Class I; Level of Evidence A). Early detection and control of masked hypertension are the keys for successful individual management of 24-hour BP control.2 An information communication technology–based anticipation approach using individual time-series big BP data is expected to dramatically suppress the incidence of cardiovascular events and improve the health and longevity of patients worldwide.4,5Four Asian studies have demonstrated that morning home BP is a better prognostic predictor of cardiovascular events than clinic BP. These were the general population-based Ohasama Study,32 the general practitioner-based J-HOP study (Japan Morning Surge-Home Blood Pressure),33 a hypertensive outpatient trial on medication (HOMED-BP, Hypertension Objective Treatment Based on Measurement by Electrical Devices of Blood Pressure),34 and the largest nationwide Japanese real-world observational study (HONEST).7,35 Indeed, in the HONEST study, a morning home SBP of ≈125 mm Hg was associated with minimal risk for both stroke and coronary artery disease events.Because of Asian lifestyle, individuals are unlikely to measure their evening home BP before dinner, and thus it is recommended that the evening home BP be measured just before going to bed.27–30 We stressed the importance of morning home BP in clinical practice27–30 because morning home BP has shown better reproducibility than evening home BP or clinic BP.36 However, the measurement of evening home BP just before going to bed is strongly affected by the individual's dinner (including alcohol consumption) and evening behavior (eg, bathing in the evening is common in Asia).37 Thus, morning home BP control is important from a practical standpoint, especially in Asian hypertensive patients.The next step after controlling morning home BP is the management of uncontrolled nocturnal hypertension. The 2017 AHA/ACC guidelines defined a threshold of nocturnal BP (110/65 mm Hg) corresponding to clinic, home, and daytime BPs (all 130/80 mm Hg).1Figure 3 shows the night-time and morning home SBP control status in the J-HOP study. A morning home SBP of 135 mm Hg corresponds to a night-time home SBP of 120 mm Hg, which is the threshold defined by the Seventh Report of the Joint National Committee on Prevention while the 110 mm Hg threshold of the 2017 ACC/AHA guidelines corresponds to a morning home SBP of 130 mm Hg. In those with well-controlled morning home SBP, a significant proportion of patients continue to have uncontrolled nocturnal hypertension (30% by the criteria of 135 mm Hg for morning home SBP and 120 mm Hg for night-time SBP; 56% by the criteria of 130 mm Hg for morning home SBP and 110 mm Hg for night-time SBP). Thus, even after controlling morning BP, there is still a remaining risk of uncontrolled nocturnal hypertension. The new criteria for night-time BP threshold from the 2017 ACC/AHA guidelines might not contribute to a reduction in masked uncontrolled hypertension. Thus, to detect the residual risk of uncontrolled nocturnal hypertension, ambulatory BP monitoring or nocturnal home BP monitoring would be recommended even in patients with well-controlled normotension for clinic BP and morning home BPs, especially in the high-risk Asian hypertensive patients having diabetes mellitus, chronic kidney disease, sleep apnea, or sustained organ damages, such as left ventricular hypertrophy or albuminuria.Download figureDownload PowerPointFigure 3. Shift in the prevalence of nocturnal hypertension classified by the new American Heart Association/American College of Cardiology 2017 guidelines (red) from that classified by the previous Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure guidelines (black) in subjects in the J-HOP study (Japan Morning Surge-Home Blood Pressure; 2791 medicated hypertensives). SBP indicates systolic blood pressure.As a feasibility study of the HOPE Asia Network, we have started the Asia [email protected] study, which will determine the prevalence of masked uncontrolled morning home BP and the characteristics of home BP variability in medicated hypertensive patients living in 12 Asian counties.38 The Asia [email protected] study is the first cross-sectional study of home BP in Asia using the same protocol and the same home BP monitoring device in currently medicated hypertensive outpatients of participating countries. It seeks to identify the regional, country-based, and ethnic differences in the current BP control status. Through this and other HOPE Asia Network activities, we hope to contribute to advances in the management of hypertension and the prevention of cardiovascular–renal disease, with the ultimate goal of achieving zero cardiovascular events in Asia.Conclusions and PerspectivesRegardless of whether we use the term hypertension to describe a BP status >130/80 mm Hg, the core concept in the 2017ACC/AHA guidelines—namely, earlier and tighter BP control over 24 hours—will contribute to more sustained target organ protection and cardiovascular disease prevention in Asia. To determine the feasibility and benefit of 130/80 mm Hg as a diagnostic threshold and management goal of BP, we have begun to collect the previous Asian evidence to reach a consensus, and we are also promoting further clinical research in Asian countries by facilitating the HOPE Asia Network activity.DisclosuresK. Kario received research funding from Teijin Pharma, Ltd, Omron Healthcare Co, Ltd, Fukuda Denshi, Bayer Yakuhin, Ltd, A&D Co, Ltd, Daiichi Sankyo Company, Ltd, Pfizer Inc, Mochida Pharmaceutical Co, Ltd, EA Pharma, Boehringer Ingelheim Japan Inc, Tanabe Mitsubishi Pharma Corporation, Shionogi & Co, Ltd, MSD K.K., Sanwa Kagaku Kenkyusho Co, Ltd, Bristol-Myers Squibb K.K., and honoraria from Takeda Pharmaceutical Co, Ltd and Omron Healthcare Co, Ltd. J.-G. Wang received research funding from Astra-Zeneca, Bayer, MSD, OMRON, Pfizer, and Philips and honoraria from Astra-Zeneca, Bayer, Daiichi-Sankyo, MSD, Pfizer, Sanofi, Servier, and Takeda.FootnotesThe opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.Correspondence to Kazuomi Kario, Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Hypertension Cardiovascular Outcome Prevention and Evidence in Asia (HOPE Asia) Network, 3311-1 Yakushiji, Shimotsuke, Tochigi 329–0498, Japan. E-mail [email protected]References1. Whelton PK, Carey RM, Aronow WS, et al. 2017ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Hypertension. 2018; 71:e13–e115. doi: 10.1161/HYP.0000000000000065.LinkGoogle Scholar2. Kario K. Global Impact of 2017 American Heart Association/American College of Cardiology Hypertension Guidelines: a perspective from Japan.Circulation. 2018; 137:543–545. doi: 10.1161/CIRCULATIONAHA.117.032851.LinkGoogle Scholar3. Wang JG, Liu L. Global Impact of 2017 American College of Cardiology/American Heart Association Hypertension Guidelines: a perspective from China.Circulation. 2018; 137:546–548. doi: 10.1161/CIRCULATIONAHA.117.032890.LinkGoogle Scholar4. Kario K. Evidence and perspectives on the 24-hour management of hypertension: hemodynamic biomarker-initiated 'Anticipation Medicine' for zero cardiovascular event.Prog Cardiovasc Dis. 2016; 59:262–281. doi: 10.1016/j.pcad.2016.04.001.CrossrefMedlineGoogle Scholar5. Kario K, Tomitani N, Kanegae H, Yasui N, Nishizawa M, Fujiwara T, Shigezumi T, Nagai R, Harada H. Development of a new ICT-based multisensor blood pressure monitoring system for use in hemodynamic biomarker-initiated anticipation medicine for cardiovascular disease: the National IMPACT Program Project.Prog Cardiovasc Dis. 2017; 60:435–449. doi: 10.1016/j.pcad.2017.10.002.CrossrefMedlineGoogle Scholar6. Kario K, Chen CH, Park S, Park CG, Hoshide S, Cheng HM, Huang QF, Wang JG. Consensus document on improving hypertension management in Asian patients, taking into account Asian characteristics.Hypertension. 2018; 71:375–382. doi: 10.1161/HYPERTENSIONAHA.117.10238.LinkGoogle Scholar7. Kario K, Saito I, Kushiro T, Teramukai S, Ishikawa Y, Mori Y, Kobayashi F, Shimada K. Home blood pressure and cardiovascular outcomes in patients during antihypertensive therapy: primary results of HONEST, a large-scale prospective, real-world observational study.Hypertension. 2014; 64:989–996. doi: 10.1161/HYPERTENSIONAHA.114.04262.LinkGoogle Scholar8. Perkovic V, Huxley R, Wu Y, Prabhakaran D, MacMahon S. The burden of blood pressure-related disease: a neglected priority for global health.Hypertension. 2007; 50:991–997. doi: 10.1161/HYPERTENSIONAHA.107.095497.LinkGoogle Scholar9. Hoshide S, Wang JG, Park S, Chen CH, Cheng HM, Huang QF, Park CG, Kario K. Treatment considerations of clinical physician on hypertension management in Asia.Curr Hypertens Rev. 2016; 12:164–168.CrossrefMedlineGoogle Scholar10. Kario K; HOPE Asia (Hypertension Cardiovascular Outcome Prevention and Evidence in Asia) Network. The HOPE Asia Network for "zero" cardiovascular events in Asia.J Clin Hypertens (Greenwich). 2018; 20:212–214. doi: 10.1111/jch.13185.CrossrefMedlineGoogle Scholar11. Chia YC, Buranakitjaroen P, Chen CH, et al; HOPE Asia Network. Current status of home blood pressure monitoring in Asia: statement from the HOPE Asia Network.J Clin Hypertens (Greenwich). 2017; 19:1192–1201. doi: 10.1111/jch.13058.CrossrefMedlineGoogle Scholar12. Son PT, Quang NN, Viet NL, Khai PG, Wall S, Weinehall L, Bonita R, Byass P. Prevalence, awareness, treatment and control of hypertension in Vietnam-results from a national survey.J Hum Hypertens. 2012; 26:268–280. doi: 10.1038/jhh.2011.18.CrossrefMedlineGoogle Scholar13. Muntner P, Carey RM, Gidding S, Jones DW, Taler SJ, Wright JT, Whelton PK. Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline.Circulation. 2018; 137:109–118. doi: 10.1161/CIRCULATIONAHA.117.032582.LinkGoogle Scholar14. Ishikawa Y, Ishikawa J, Ishikawa S, Kayaba K, Nakamura Y, Shimada K, Kajii E, Pickering TG, Kario K; Jichi Medical School Cohort Investigators Group. Prevalence and determinants of prehypertension in a Japanese general population: the Jichi Medical School Cohort Study.Hypertens Res. 2008; 31:1323–1330. doi: 10.1291/hypres.31.1323.CrossrefMedlineGoogle Scholar15. Katsuya T, Ishikawa K, Sugimoto K, Rakugi H, Ogihara T. Salt sensitivity of Japanese from the viewpoint of gene polymorphism.Hypertens Res. 2003; 26:521–525.CrossrefMedlineGoogle Scholar16. Powles J, Fahimi S, Micha R, Khatibzadeh S, Shi P, Ezzati M, Engell RE, Lim SS, Danaei G, Mozaffarian D; Global Burden of Diseases Nutrition and Chronic Diseases Expert Group (NutriCoDE). Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide.BMJ Open. 2013; 3:e003733.CrossrefMedlineGoogle Scholar17. Kario K. Essential Manual on Perfect 24-hour Blood Pressure Management from Morning to Nocturnal Hypertension: Up-to-date for Anticipation Medicine. Tokyo, Japan: Wiley-Blackwell; 2018:1–308.Google Scholar18. Nakano M, Eguchi K, Sato T, Onoguchi A, Hoshide S, Kario K. Effect of intensive salt-restriction education on clinic, home, and ambulatory blood pressure levels in treated hypertensive patients during a 3-month education period.J Clin Hypertens (Greenwich). 2016; 18:385–392. doi: 10.1111/jch.12770.CrossrefMedlineGoogle Scholar19. Omboni S, Aristizabal D, De la Sierra A, et al; ARTEMIS (international Ambulatory blood pressure Registry: TEleMonitoring of hypertension and cardiovascular rISk project) Investigators. Hypertension types defined by clinic and ambulatory blood pressure in 14 143 patients referred to hypertension clinics worldwide. Data from the ARTEMIS study.J Hypertens. 2016; 34:2187–2198. doi: 10.1097/HJH.0000000000001074.CrossrefMedlineGoogle Scholar20. Hoshide S, Kario K, de la Sierra A, Bilo G, Schillaci G, Banegas JR, Gorostidi M, Segura J, Lombardi C, Omboni S, Ruilope L, Mancia G, Parati G. Ethnic differences in the degree of morning blood pressure surge and in its determinants between Japanese and European hypertensive subjects: data from the ARTEMIS study.Hypertension. 2015; 66:750–756. doi: 10.1161/HYPERTENSIONAHA.115.05958.LinkGoogle Scholar21. Kario K, Bhatt DL, Brar S, Bakris GL. Differences in dynamic diurnal blood pressure variability between Japanese and American treatment-resistant hypertensive populations.Circ J. 2017; 81:1337–1345. doi: 10.1253/circj.CJ-16-1237.CrossrefMedlineGoogle Scholar22. Li Y, Wang JG. Isolated nocturnal hypertension: a disease masked in the dark.Hypertension. 2013; 61:278–283. doi: 10.1161/HYPERTENSIONAHA.111.00217.LinkGoogle Scholar23. Li Y, Wang JG, Gao P, Guo H, Nawrot T, Wang G, Qian Y, Staessen JA, Zhu D. Are published characteristics of the ambulatory blood pressure generalizable to rural Chinese? The JingNing population study.Blood Press Monit. 2005; 10:125–134.CrossrefMedlineGoogle Scholar24. Li Y, Staessen JA, Lu L, Li LH, Wang GL, Wang JG. Is isolated nocturnal hypertension a novel clinical entity? Findings from a Chinese population study.Hypertension. 2007; 50:333–339. doi: 10.1161/HYPERTENSIONAHA.107.087767.LinkGoogle Scholar25. Kimura G, Dohi Y, Fukuda M. Salt sensiti

Abstract:HomeHypertensionVol. 50, No. 6The Burden of Blood Pressure-Related Disease Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBThe Burden of Blood Pressure-Related DiseaseA Neglected Priority for Global Health Vlado Perkovic, Rachel Huxley, Yangfeng Wu, Dorairaj Prabhakaran and Stephen MacMahon Vlado PerkovicVlado Perkovic From the George Institute for International Health (V.P., R.H., S.M.), University of Sydney, Sydney, Australia; Department of Nephrology (V.P.), Royal North Shore Hospital, Sydney, Australia; George Institute for International Health (Y.W.), Peking University Health Science Centre, Beijing, China; Department of Cardiology (D.P.), All India Institute of Medical Sciences, New Delhi, India; and Royal Prince Alfred Hospital (S.M.), Sydney, Australia. , Rachel HuxleyRachel Huxley From the George Institute for International Health (V.P., R.H., S.M.), University of Sydney, Sydney, Australia; Department of Nephrology (V.P.), Royal North Shore Hospital, Sydney, Australia; George Institute for International Health (Y.W.), Peking University Health Science Centre, Beijing, China; Department of Cardiology (D.P.), All India Institute of Medical Sciences, New Delhi, India; and Royal Prince Alfred Hospital (S.M.), Sydney, Australia. , Yangfeng WuYangfeng Wu From the George Institute for International Health (V.P., R.H., S.M.), University of Sydney, Sydney, Australia; Department of Nephrology (V.P.), Royal North Shore Hospital, Sydney, Australia; George Institute for International Health (Y.W.), Peking University Health Science Centre, Beijing, China; Department of Cardiology (D.P.), All India Institute of Medical Sciences, New Delhi, India; and Royal Prince Alfred Hospital (S.M.), Sydney, Australia. , Dorairaj PrabhakaranDorairaj Prabhakaran From the George Institute for International Health (V.P., R.H., S.M.), University of Sydney, Sydney, Australia; Department of Nephrology (V.P.), Royal North Shore Hospital, Sydney, Australia; George Institute for International Health (Y.W.), Peking University Health Science Centre, Beijing, China; Department of Cardiology (D.P.), All India Institute of Medical Sciences, New Delhi, India; and Royal Prince Alfred Hospital (S.M.), Sydney, Australia. and Stephen MacMahonStephen MacMahon From the George Institute for International Health (V.P., R.H., S.M.), University of Sydney, Sydney, Australia; Department of Nephrology (V.P.), Royal North Shore Hospital, Sydney, Australia; George Institute for International Health (Y.W.), Peking University Health Science Centre, Beijing, China; Department of Cardiology (D.P.), All India Institute of Medical Sciences, New Delhi, India; and Royal Prince Alfred Hospital (S.M.), Sydney, Australia. Originally published22 Oct 2007https://doi.org/10.1161/HYPERTENSIONAHA.107.095497Hypertension. 2007;50:991–997Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: October 22, 2007: Previous Version 1 The importance of high blood pressure as a major cause of common serious diseases has been recognized in most Western countries for ≈50 years. Before that, malignant hypertension was a frequent reason for hospital admission and a common cause of death.1 Safe and effective antihypertensive drugs were first developed in the 1960s and were shown to dramatically improve the prognosis associated with malignant hypertension.2,3 Over the next few decades, the widespread use of an expanding armamentarium of blood pressure–lowering drugs to patients at risk of malignant hypertension effectively eradicated this condition from most developed countries. Subsequently, the provision of blood pressure–lowering treatments to a much broader group of patients at risk of serious cardiovascular diseases, such as stroke and coronary heart disease, among whom blood pressure levels were often only modestly elevated, contributed importantly to the declines in stroke and coronary disease deaths rates experienced by most Western populations.4However, the situation in higher-income countries stands in stark contrast to that experienced by their lower-income neighbors. The overall burden of blood pressure–related diseases is rapidly rising in countries such as India and China as a consequence of the aging population, increasing urbanization, and increases in age-specific rates of conditions such as stroke.5,6 Even war-torn countries and those ravaged by HIV/AIDS, such as some in sub-Saharan Africa, incur a huge burden of blood pressure–related diseases. In several such populations, cerebral hemorrhage is the leading cause of death in adults.7 Although safe and effective antihypertensive treatment could be provided in these regions with a range of generic products from <1 cent per person per day, the reality is that most people for whom such drugs are clearly indicated receive no treatment whatsoever. In this regard, the antihypertensive care available for a large proportion of the world's population remains much as it was in the 1950s before the development of diuretics and β-blockers. In this review, we describe the global burden of blood pressure–related diseases, discuss some of the barriers to the implementation of effective preventive programs, and consider practical solutions that could be implemented in resource-poor settings.Prevalence of High Blood Pressure in Higher- and Lower-Income RegionsThere is now compelling evidence that the level of systolic blood pressure at which the risks of stroke and coronary heart disease begin to increase is ≈115 mm Hg.8–10 On this basis, the majority of adults in most higher- and lower-income populations have nonoptimal blood pressure.11,12 However, there are important regional variations in blood pressure distributions, even taking into account potential differences in the technique of blood pressure measurement. For example, in both sexes, for all ages >45 years, average blood pressure levels are highest in populations from Eastern Europe and Russia. Average levels are also particularly high in the Middle East, North Africa, and parts of sub-Sahara Africa.12Classifications of hypertension vary, but on the basis of a single blood pressure measurement >140 mm Hg systolic or 90 mm Hg diastolic, ≈1 in 4 adults, worldwide, would be so classified (Table 1).13 Currently, this equates to ≈1 billion individuals, and this number is expected to grow to >1.5 billion (≈30% of the global population) by 2025, solely as a consequence of increases in both total population size and the proportions within populations reaching older ages. In higher-income regions, the number of hypertensive individuals is predicted to grow by 70 million people from 2000 to 2025, whereas in lower-income regions, the number is predicted to grow by >500 million over the same period. In China and India alone, the total number with a systolic blood pressure >140 mm Hg or a diastolic blood pressure >90 mm Hg is expected to increase to >500 million by 2025. Table 1. Estimated Number of Individuals Aged ≥20 Years With Blood Pressure >140/90 mm Hg in 2000 and Predicted Number of Affected Individuals in 2025RegionPrevalence 2000, MillionsPredicted Prevalence 2025, MillionsIncrease, MillionsAdapted from Kearney et al13 with permission from Elsevier.Established market economies239.5309.770.2Latin America and the Caribbean114.3200.686.3Former socialist economies93.1103.710.6Middle East crescent73.8152.678.8China181.6299.2117.6India118.2213.595.3Other Asia and islands71.4129.458.0Sub-Saharan Africa79.8150.770.9Total971.71559.4587.7Although demographic changes in populations will have the greatest short-term consequences for changes in population blood pressure distributions and hypertension prevalence, other factors are likely to augment these changes. In particular, progress in economic development, with consequent increases in obesity because of greater food availability and choice, and a reduction in physical activity can be expected to further increase mean blood pressure levels and the proportion with high blood pressure in lower income regions such as China and India.14–16Effects of Blood Pressure on Disease Burden in Higher- and Lower-Income RegionsLarge-scale epidemiological studies have clearly demonstrated the enormous impact of nonoptimal blood pressure levels on the risks of major cardiovascular events in both higher- and lower-income regions.8,9,17 The Asia Pacific Cohort Studies Collaboration, which involved >500 000 individuals followed for several years on average, has demonstrated direct continuous associations of usual levels of systolic and diastolic blood pressure with the risks of coronary heart disease and stroke in both white and Asian populations.9,18Overall, the association of blood pressure with stroke risk was about twice as steep as that with coronary disease risk, and whereas the association with coronary risk was identical in the Asian and white populations, the association with stroke risk was steeper among Asians (Figure 1). This appeared, in part, to be the consequence of the greater proportion of strokes that were hemorrhagic in the Asian population and the steeper association of blood pressure with hemorrhagic rather than ischemic stroke. There was also evidence of a steeper association of blood pressure with hemorrhagic stroke among Asians compared with whites.10Download figureDownload PowerPointFigure 1. The higher risk of (A) fatal and nonfatal coronary heart disease and (B) stroke, associated with higher systolic blood pressure (SBP) levels by age and region in the Asia Pacific Cohort Studies Collaboration.There is little direct evidence about the effects of blood pressure on cardiovascular disease risks in other lower-income regions outside of Asia. However, on the basis of regional evidence about blood pressure distributions and the burden of death and disability from cardiovascular disease, the contribution of blood pressure to total cardiovascular disease burden can been estimated for all regions of the world.11,19 Those analyses showed that approximately two thirds of all stroke and half of all coronary disease can be attributed to nonoptimal blood pressure. This represents ≈7 million deaths and 64 million disability-adjusted life years each year. Lower-income countries suffered approximately two thirds of the total burden of blood pressure–related disease. The 2 countries experiencing the greatest burden of blood pressure–related diseases were India and China. However, whereas stroke was the most common type of blood pressure–related disease in China, coronary disease was more common in India. Compared with higher-income regions, these and other lower-income regions had a greater proportion of blood pressure–related disease occur among people of middle age. In the poorest regions, including many in Africa, most blood pressure–related disease occurred among individuals aged 40 to 59 years.11The relationship between blood pressure levels and noncardiovascular diseases risk has been less well defined, although similar relationships between blood pressure levels and the risk of end-stage kidney disease have been described in large studies of white20 and Asian populations.21 Given the very large increases in diabetes (and the inevitable attendant increases in diabetic kidney disease) being experienced across the developing world,22,23 it is likely that nonoptimal blood pressure will be responsible for a large proportion of the resulting disease burden.Effects of Blood Pressure Lowering on Disease Risks in Higher- and Lower-Income RegionsThe effects of blood pressure lowering with a range of drug therapies have been demonstrated in a large series of clinical trials. Evidence from these trials has been synthesized by the Blood Pressure Lowering Treatment Trialists' Collaboration and others, demonstrating that the magnitude of the blood pressure reduction achieved is a more important predictor of the cardiovascular benefits obtained than the choice of drug.24–26 In a wide variety of patient populations, blood pressure lowering reduced the risk of coronary heart disease and stroke by roughly the magnitude predicted from the observational evidence about the association of blood pressure with cause-specific cardiovascular events. In general, a 10-mm Hg reduction in systolic blood pressure produced approximately a 20% to 25% reduction in major cardiovascular events, with larger effects on stroke than coronary outcomes.There was some evidence of relatively minor differences between drug classes in their effects on some cause-specific outcomes. For example, for any given blood pressure reduction, there appeared to be an ≈10% greater reduction in coronary heart disease risk with angiotensin-converting enzyme inhibitor treatment than with other therapy.27 However, overall the net effects on total cardiovascular disease risk of all of the common drug classes were broadly equivalent. Indeed, treatment based on a diuretic, one of the least expensive drug classes, produced as much reduction in overall risk as did treatment based on any of the other more expensive drug classes. Because diuretics are available for as little as a few cents per week, they provide the most affordable basis for antihypertensive therapy in resource-poor settings.Most trials have been conducted in higher-income countries, and few have recruited enough patients from lower-income regions to provide reliable evidence about the effects of treatment in resource-poor settings. However, 2 studies have recruited large numbers of patients from Asia, in particular, China, as well as Western countries. In the Perindopril Protection Against Recurrent Stroke Study Trial28 of blood pressure lowering among patients with a history of cerebrovascular disease, participants recruited from Asian countries derived at least an equivalent benefit from the study therapy as did participants from Western countries (Figure 2).29 Similarly, in the Action in Diabetes and Vascular Disease Trial30 of blood pressure lowering among patients with type 2 diabetes, the effects of treatment were the same among participants recruited from Asia and those recruited from elsewhere. A few trials have been conducted exclusively in Asian populations (eg, the Felodipine Event Reduction Trial31), and these studies have generally reported benefits that are similar to those typically observed in studies conducted in Western populations. Download figureDownload PowerPointFigure 2. The effects of a perindopril-based blood pressure–lowering regimen on the risk of subsequent stroke among Asian and Caucasian participants in the Perindopril Protection Against Recurrent Stroke Study. Reproduced from Rodgers et al.29Although some higher-income countries may have the resources required to provide blood pressure–lowering treatment to most or all of those with hypertension, this is not affordable or practical for most lower-income countries. For example, for India or China to provide treatment for all of those with hypertension would require each of these countries to deliver such care to a population of ≈200 million.13 For such countries, it is essential that treatment policy targets those most in need, for whom benefits will be greatest and costs easiest to justify. One approach that has been widely promulgated by the World Health Organization32 and European33 guidelines is to base treatment policies on estimated absolute disease risk rather than on blood pressure levels alone. If the target for blood pressure–lowering therapy was a 25% 10-year risk of a major cardiovascular event, then this would imply the provision of treatment to ≈50 million people in of each China and India and ≈20 million people in each of Africa and South America (Figure 3). Such a treatment strategy has been assessed as being cost-effective for many lower-income regions.34 However, for some of the poorest countries, blood pressure–lowering treatment may need to be restricted to even higher-risk individuals, perhaps only those who have moderate-to-severe hypertension or a history of significant cardiovascular or renal disease. Download figureDownload PowerPointFigure 3. Total number of individuals (in millions) with an estimated 10-year risk of cardiovascular disease of ≥25% according to World Health Organization region. AFR indicates Africa; AMR, the Americas; EMR, Eastern Mediterranean; EUR, Europe; SEAR, Southeast Asia; WPR, Western Pacific Region; A, very low child mortality and very low adult mortality; B, low child mortality and low adult mortality; C, low child mortality and high adult mortality; D, high child mortality and high adult mortality; E, high child mortality and very high adult mortality. Developed by Dr A. Rodgers from data collected for Ezzati et al.19Barriers to the Prevention of Blood Pressure–Related Diseases in Lower-Income RegionsDrug CostsThere are many barriers to the provision of appropriate blood pressure–lowering therapy in resource-poor settings, but drug costs should not be one of them. For example, the diuretic hydrochlorothiazide can be purchased internationally for ≈0.3 cents per 25-mg tablet, the β-blocker atenolol for ≈1 cent per 100-mg tablet, and the angiotensin-converting enzyme inhibitor enalapril for 2 to 3 cents per 20-mg tablet35 (Table 2). On this basis, 1 year's supply of hydrochlorothiazide should cost approximately $1 per person, and the total annual cost of purchasing drug for all of those with a 25% 10-year risk of a major cardiovascular event would be approximately $50 million in each of China and India and approximately $20 million in each of Africa and South America. Assuming that such treatment reduced the 10-year risk of a major cardiovascular event from 25% to 20%, the drug costs for the prevention of each fatal or serious event would be approximately $200. Such costs are within the financial capacity of all but the very poorest countries. However, as experience in sub-Saharan Africa has shown with respect to donated or heavily subsidized antiretroviral drugs, the absence of functional primary health care services in many countries means that even a free or inexpensive drug cannot be reliably provided to those in need.36 In addition, whereas the cost of some generic drugs from wholesalers may be low, the price at which the same drug is provided to a patient is often grossly inflated. Moreover, there are often financial incentives for healthcare providers to selectively prescribe more expensive drugs despite there being no clear advantage over cheaper drugs, such as diuretics. Table 2. International Median Supplier Reference Cost of Selected Blood Pressure–Lowering AgentsDrug ClassExample Agent, Dose, mgMedian Supplier Price, US Cents per DoseData are from McFadyen.35 ACE indicates angiotensin-converting enzyme.β-BlockerAtenolol, 501.1Calcium channel blockerNifedipine sustained release, 201.9DiureticHydrochlorothiazide, 250.3ACE inhibitorEnalapril, 204.5Structural BarriersThe prevention of blood pressure–related diseases requires a primary health care system that can identify those at high risk, ensure regular monitoring of their health status, and provide an uninterrupted appropriate and affordable treatment supply. Each of these poses its own unique challenges in many lower-income regions. With respect to identifying those at high risk, algorithms developed for Western populations typically require laboratory blood tests for total, low-density lipoprotein, and high-density lipoprotein cholesterol and fasting blood glucose.37 In many resource-poor settings, laboratory access can be difficult and expensive. In regions in which HIV and hepatitis B infection are common, there may also be professional and community concerns about screening programs that involve phlebotomy. Therefore, screening algorithms are required that take special account of these factors. For example, a screening algorithm that includes gender, age, cardiovascular disease history, blood pressure, weight and height, and a urine dipstick test for glucose and protein is likely to be more practical and may well provide much of the predictive value of more complex blood-based assessments.32 In addition, such algorithms should, wherever possible, use regional data on morbidity and mortality, because background rates vary considerably between regions.38 Although there are few data available about the proportion of high-risk individuals who are aware of their status, there are more data available about the proportion aware of having high blood pressure. For example, in lower-income regions such as India, only a minority of all those with high blood pressure are aware of their condition (Table 3).39–43 Improving the identification of individuals at high risk of blood pressure–related diseases will require educational programs aimed at both healthcare providers and consumers. The provision of provider incentives for screening and risk assessment is likely to be an important determinant of success. Table 3. Prevalence, Awareness, and Treatment Status of Hypertension (≥140/90 mm Hg) in Studies Conducted Among Nonrepresentative Indian SubpopulationsStudyPrevalence, %Awareness, % of PrevalentTreatment, % of PrevalentReddy et al, 20064027.737.330.3Prabhakaran et al, 20054130.031.5Deepa et al, 20034222.137.318.7Hypertension Study Group, 200139 Urban7046.641.6 Rural5561.453.0Gupta et al, 19954330.913.18.0The capacity to provide long-term monitoring of those at high risk is an essential criterion for the effective prevention of blood pressure–related diseases. In many situations, primary healthcare services have provided only episodic care with little record kept of previous visits.44 In part, this reflects the priority given to the management of acute conditions, such as infections, trauma, and childbirth, over chronic conditions that require treatment over many years. It is now clear that primary healthcare services in resource-poor settings must be adapted to provide long-term care, not only for the management of cardiovascular and other serious noncommunicable diseases but also for the management of HIV infection with long-term antiretroviral therapy.44 Central to this is an improvement in the quality of medical charts, which are required for continuity of care. Once again, provider incentives are likely to be helpful in achieving acceptable levels of monitoring and follow-up.Continuity of care also requires access to an uninterrupted and affordable drug supply. In many situations, neither is available. Drug distribution chains in many rural regions can be unreliable, to the degree that even hospitals can often be without blood pressure–lowering drugs for the treatment of hypertensive emergencies. In other regions, drug distribution chains are more reliable, but the involvement of several distributors can inflate costs significantly. Finally, in many lower-income countries, there is no separation between prescription and supply, resulting in perverse incentives to prescribe higher-cost drugs and to add profit margins on top of supply costs. In such circumstances there is a need to regulate drug supply such that continuity is assured and charges to patients are kept within reasonable limits. There is also a need to separate prescription and supply to avoid drug selection being affected by financial rewards to the prescriber. In these circumstances, practical guidelines designed specifically for use in resource-poor settings are required in place of the complex and largely impractical international guidelines developed primarily with higher-income countries in mind. Guidelines for lower-income regions should be developed with due regard to the important role played by nonphysician health workers, who provide a large proportion of primary healthcare services in countries such as China. Again, incentives to reward the prescription of guideline-based blood pressure–lowering therapy are likely to be helpful.Policy BarriersIn many countries there are policy barriers to the implementation of blood pressure–lowering treatment programs. Most common is the restrictive focus of prevention programs on infectious disease and sometimes on HIV/AIDS alone. Many lower-income countries face a double burden of communicable and noncommunicable disease, yet few allocate resources to demands on the basis of cost-effectiveness or even disease burden. Multilateral organizations, such as the World Health Organization and the World Bank, have been partly responsible for this unbalanced approach through the setting of Millennium Development Goals45 that excluded any mention of chronic disease prevention and through the setting of implausibly high targets for antiretroviral therapy implementation.46 Notably, the failure to achieve these targets47 at least in part reflected the failure to deploy effective strategies to create the primary healthcare networks required to deliver any form of chronic care.Fortunately, in recent years both World Health Organization48 and the World Bank49 have recognized the importance of chronic diseases, including blood pressure–related diseases, as a cause not only of premature death and disability but also as a threat to social and economic development. This may herald the beginning of a rebalancing of investment priorities for health care in at least some lower-income countries. However, the prioritization of blood pressure control as a strategy to improve health status will require evidence that worthwhile benefits can be achieved at a price that is affordable. This requires a markedly different approach to that adopted in higher-income countries in which treatment programs are primarily physician centered and often use expensive diagnostic procedures (eg, 24-hour blood pressure measurement or echocardiography) and on-patent drugs. As indicated above, lower-income regions require approaches that can be implemented by nonphysician healthcare workers using simple assessment tools and low-cost drugs. They also require a targeted focus on a select group of individuals at particularly high risk of cardiovascular or renal diseases. Goals that involve the identification and treatment of all of those who might be classified as hypertensive, irrespective of disease risk, are unrealistic and, as a consequence, counterproductive. Different strategies are probably required in urban and rural areas, but both require outreach programs to access disadvantaged population subgroups.Research Relevant to the Prevention of Blood Pressure–Related Diseases in Lower-Income RegionsStrategies to reduce the burden of blood pressure–related diseases in lower-income countries requires research. Although most requirements are for operational research, there is still a need for research that will provide evidence about the effects of novel interventions for disease prevention that may be of special relevance to particular populations. Research into region-specific strategies targeting important determinants of blood pressure, such as salt intake or obesity, may yield useful information. However, the greatest current need is for operational research to determine how best to implement affordable drug-based preventive programs that have proven effective in reducing blood pressure–related diseases, such as stroke and coronary heart disease. Novel approaches are required, because the models developed for use in higher-income countries are neither affordable nor practical given current and foreseeable resource constraints.One research strategy that may have particular merit is the conduct of cluster-randomized trials of new healthcare delivery strategies for the prevention of blood pressure–related diseases. This could involve the development of regionally tailored packages of interventions targeted to healthcare providers and designed to increase the identification of high-risk individuals and to improve their treatment according to evidence-based, resource-sensitive algorithms. Key components of such a package would need to include healthcare provider training, simple algorithms for screening, treatment and follow-up, and reliable drug supply. Intervention packages targeted to consumers could also be assessed. Components might include free or subsidized drugs, health education about blood pressure and cardiovascular disease, and community programs aimed at increasing self-referral for risk assessment. Although such research programs are challenging to implement and require significant resources, they are still likely to be much less expensive than the trial programs required for the development and registration of new antihypertensive drugs and of much greater potential benefit for the prevention of blood pressure–related diseases globally.PerspectivesNonoptimal blood pressure is the leading cause of death globally, responsible for 7 million deaths annually. Most of these deaths and most of the disability caused by blood pressure–related diseases are suffered by people in lower-income countries. The resulting burden threatens already fragile health systems, as well as social and economic development. Yet, very few people receive blood pressure–lowering therapy in many lower-income countries. The reasons for this are complex but largely involve the limitations of primary healthcare systems to deliver effective and affordable care. The solutions are also complex and will not be easily found in the approaches adopted by most higher-income countries given the costs involved. Specific solutions are required for different regional circumstances. These need to reflect competing disease burdens, financial resources, human resources, and cultural and societal values regarding the relative importance of strategies focused on disease prevention as opposed

Could 130/80 Mm Hg Be Adopted As the Diagnostic Threshold and Management Goal of Hypertension in Consideration of the Characteristics of Asian Populations?

Mean systolic blood pressure above the control threshold in people with treated uncontrolled hypertension: a pooled, cross-sectional analysis of 55 national health surveys

Target Blood Pressure and Control Status in Asia

Consensus Document on Improving Hypertension Management in Asian Patients, Taking into Account Asian Characteristics.

One More Step Toward an Asian Hypertension Guideline

Treatment Considerations of Clinical Physician on Hypertension Management in Asia

Home Blood Pressure Control Status in 2017‐2018 for Hypertension Specialist Centers in Asia: Results of the Asia BP@Home Study

Hypertension in China: the Gap Between Policy and Practice

Management of Hypertension in the Asia-Pacific Region: A Structured Review

Target Blood Pressure in Patients with Diabetes: Asian Perspective.

A18380 the Status of Home Blood Pressure Control 2017–2018 in Specialist Hypertension Centers in Asia - Results from AsiaBP@Home, the First Standardized Study Using the Same Validated Device and Following the Same Protocol in 11 Different Asian Countries and Regions

Expert Panel Consensus Recommendations for Ambulatory Blood Pressure Monitoring in Asia: the HOPE Asia Network.

Toward “zero” Cardiovascular Events in Asia: the HOPE Asia Network

Chinese Physicians’ Perspectives on the 2017 American College of Cardiology/American Heart Association Hypertension Guideline: A Mobile App-Based Survey

STEP to blood pressure management of elderly hypertension: evidence from Asia

The Burden of Blood Pressure-Related Disease

The HOPE Asia Network Consensus on Blood Pressure Measurements Corresponding to Office Measurements: Automated Office, Home, and Ambulatory Blood Pressures

Blood Pressure Goals: A Moving Target

Prevalence and Treatment of Hypertension in China: Impacts of 2017 American College of Cardiology/American Heart Association High Blood Pressure Guideline.

Systolic Hypertension: An Increasing Clinical Challenge In Asia

Ambulatory blood pressure monitoring profiles in Asia